...
afmd-img

Affimed NV, Common Stock

AFMD

NMQ

$1.18

-$0.08

(-6.35%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$20.65M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
770.95K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.10
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.15 L
$8.95 H
$1.18

About Affimed NV, Common Stock

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameAFMDSectorS&P500
1-Week Return-45.87%-3.35%-2.97%
1-Month Return-60.67%-3.49%-0.66%
3-Month Return-70.2%-12.6%2.71%
6-Month Return-80%-6.91%7.21%
1-Year Return-70.5%1.19%23.04%
3-Year Return-97.92%-0.21%28.43%
5-Year Return-95.69%33.09%82.88%
10-Year Return-98.07%93.55%184.63%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue21.39M28.36M40.37M41.35M8.28M[{"date":"2019-12-31","value":51.73,"profit":true},{"date":"2020-12-31","value":68.58,"profit":true},{"date":"2021-12-31","value":97.61,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":20.01,"profit":true}]
Cost of Revenue1.55M----[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit21.39M28.36M40.37M41.35M8.28M[{"date":"2019-12-31","value":51.73,"profit":true},{"date":"2020-12-31","value":68.58,"profit":true},{"date":"2021-12-31","value":97.61,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":20.01,"profit":true}]
Gross Margin100.00%100.00%100.00%100.00%100.00%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses54.04M63.70M105.71M130.89M114.94M[{"date":"2019-12-31","value":41.28,"profit":true},{"date":"2020-12-31","value":48.67,"profit":true},{"date":"2021-12-31","value":80.76,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":87.81,"profit":true}]
Operating Income(32.38M)(34.72M)(64.03M)(88.12M)(106.66M)[{"date":"2019-12-31","value":-3237600000,"profit":false},{"date":"2020-12-31","value":-3471800000,"profit":false},{"date":"2021-12-31","value":-6403000000,"profit":false},{"date":"2022-12-31","value":-8811900000,"profit":false},{"date":"2023-12-31","value":-10666100000,"profit":false}]
Total Non-Operating Income/Expense205.00K(13.29M)5.38M4.23M964.00K[{"date":"2019-12-31","value":3.81,"profit":true},{"date":"2020-12-31","value":-247.01,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":78.67,"profit":true},{"date":"2023-12-31","value":17.91,"profit":true}]
Pre-Tax Income(32.36M)(41.37M)(57.52M)(86.00M)(105.94M)[{"date":"2019-12-31","value":-3236100000,"profit":false},{"date":"2020-12-31","value":-4136500000,"profit":false},{"date":"2021-12-31","value":-5752100000,"profit":false},{"date":"2022-12-31","value":-8600200000,"profit":false},{"date":"2023-12-31","value":-10593500000,"profit":false}]
Income Taxes4.00K1.00K2.00K2.00K3.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":25,"profit":true},{"date":"2021-12-31","value":50,"profit":true},{"date":"2022-12-31","value":50,"profit":true},{"date":"2023-12-31","value":75,"profit":true}]
Income After Taxes(32.37M)(41.37M)(57.52M)(86.00M)(105.94M)[{"date":"2019-12-31","value":-3236500000,"profit":false},{"date":"2020-12-31","value":-4136600000,"profit":false},{"date":"2021-12-31","value":-5752300000,"profit":false},{"date":"2022-12-31","value":-8600400000,"profit":false},{"date":"2023-12-31","value":-10593800000,"profit":false}]
Income From Continuous Operations(32.37M)(41.37M)(57.52M)(86.00M)(105.94M)[{"date":"2019-12-31","value":-3236500000,"profit":false},{"date":"2020-12-31","value":-4136600000,"profit":false},{"date":"2021-12-31","value":-5752300000,"profit":false},{"date":"2022-12-31","value":-8600400000,"profit":false},{"date":"2023-12-31","value":-10593800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(32.37M)(41.37M)(57.52M)(86.00M)(105.94M)[{"date":"2019-12-31","value":-3236500000,"profit":false},{"date":"2020-12-31","value":-4136600000,"profit":false},{"date":"2021-12-31","value":-5752300000,"profit":false},{"date":"2022-12-31","value":-8600400000,"profit":false},{"date":"2023-12-31","value":-10593800000,"profit":false}]
EPS (Diluted)(0.50)(0.55)(0.49)(0.60)(1.92)[{"date":"2019-12-31","value":-50,"profit":false},{"date":"2020-12-31","value":-55,"profit":false},{"date":"2021-12-31","value":-49,"profit":false},{"date":"2022-12-31","value":-60,"profit":false},{"date":"2023-12-31","value":-192,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

AFMD
Cash Ratio 1.49
Current Ratio 1.93

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AFMD
ROA (LTM) -49.31%
ROE (LTM) -124.08%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AFMD
Debt Ratio Lower is generally better. Negative is bad. 0.57
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.43

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AFMD
Trailing PE NM
Forward PE NM
P/S (TTM) 2.78
P/B 1.14
Price/FCF NM
EV/R 8.70
EV/Ebitda 1.13
PEG NM

FAQs

What is Affimed NV share price today?

Affimed NV (AFMD) share price today is $1.18

Can Indians buy Affimed NV shares?

Yes, Indians can buy shares of Affimed NV (AFMD) on Vested. To buy Affimed NV from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AFMD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Affimed NV be purchased?

Yes, you can purchase fractional shares of Affimed NV (AFMD) via the Vested app. You can start investing in Affimed NV (AFMD) with a minimum investment of $1.

How to invest in Affimed NV shares from India?

You can invest in shares of Affimed NV (AFMD) via Vested in three simple steps:

  • Click on Sign Up or Invest in AFMD stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Affimed NV shares
What is Affimed NV 52-week high and low stock price?

The 52-week high price of Affimed NV (AFMD) is $8.95. The 52-week low price of Affimed NV (AFMD) is $1.15.

What is Affimed NV price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Affimed NV (AFMD) is

What is Affimed NV price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Affimed NV (AFMD) is 1.14

What is Affimed NV dividend yield?

The dividend yield of Affimed NV (AFMD) is 0.00%

What is the Market Cap of Affimed NV?

The market capitalization of Affimed NV (AFMD) is $20.65M

What is Affimed NV’s stock symbol?

The stock symbol (or ticker) of Affimed NV is AFMD

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top